plans and may also be offered for free; volatility in the
advertising markets; any delay, disruption, or suspension of our supply of
prepared meals from our vendor; changes in consumer preferences and
discretionary spending; product liability and other risks from the sale of
ingested products; regulatory actions affecting our marketing activities;
and the outcome of litigation pending against us. For additional
information regarding these and other risks and uncertainties associated
with eDiets.com's business, reference is made to our Annual Report on Form
10-K for the year ended December 31, 2007, and other reports filed from
time to time with the Securities and Exchange Commission. All
forward-looking statements are current only as of the date on which such
statements are made. We do not undertake any obligation to publicly update
any forward- looking statements.
--Financial Tables Follow --
eDiets.com, Inc.
Summary of Consolidated Financial Information
(Unaudited)
(In thousands, except per share amounts)
Three Months Ended Nine Months Ended
September 30, September 30,
2008 2007 2008 2007
Revenues:
Digital plans $2,079 $4,369 $7,815 $15,625
Meal delivery 1,417 1,035 8,239 2,427
Other 1,257 1,431 3,914 4,777
Total revenues 4,753 6,835 19,968 22,829
Cost and expenses:
Cost of revenue
Digital plans 640 787 1,838 2,443
Meal delivery 1,407 944 8,530 2,233
Other 108
'/>"/>
SOURCE eDiets.com, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related medicine news :1.
eDiets.com(R) to Report Third Quarter 2008 Results on Thursday, November 13, 20082.
eDiets.com(R) Announces Q2 2008 Results3.
eDiets.com(R) Appoints New Chief Information Officer Laura Klein4.
eDiets.com(R) Announces Q1 2008 Results5.
eDiets.com(R) to Report First Quarter 2008 Results on Tuesday, May 13, 20086.
eDiets.com(R) Announces Q4 and Year End 2007 Results7.
eDiets.com(R) Updates Timing of Third Quarter 2007 Earnings Conference Call8.
Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter9.
Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer10.
Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer11.
In a Down Economy, Womens Health Company Announces Growth